

## Kilitch Drugs (India) Ltd.

9<sup>th</sup> April, 2025

To,  
The Manager - Corporate Relationship Dept.  
BSE Limited  
P. J. Towers, Dalal Street  
Fort, Mumbai - 400 001

To,  
The Manager - Corporate Compliance  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot No.C-1,  
G Block, BKC, Bandra (E),  
Mumbai 400 051

**Scrip Code: BSE - 524500**

**Scrip Code: NSE - KILITCH**

**Sub: Reply to Query LODR dated 8<sup>th</sup> April, 2025**

**Ref: Announcement regarding Completion of tenure of Independent Directors dated 7<sup>th</sup> April, 2025**

Dear Sir,

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submitted announcement on 7<sup>th</sup> April, 2025 regarding completion of tenure by Mr. Hemang Jagadish Engineer (DIN 02317989) with effect from end of working day on 31<sup>st</sup> March, 2025 and consequently ceased to be Directors of the Company.

In Schedule III, Para A, Sub Para 7(B), disclosures required to be given within 7 days are given. Further, timeline given under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is also mentioned as – timeline as specified in Sub-para 7B of Para A of schedule III.

From the above points, we interpreted the meaning that we may submit the announcement within 7 days from the date of completion of tenure. The delay was unintentional. Further, we assure that we shall comply with all applicable regulations / circulars in letter and spirit.

We request you to kindly consider the same and acknowledge the receipt.

Thanking you,

Yours Faithfully,

**For Kilitch Drugs (India) Limited**

**Mukund Mehta**  
**Managing Director**

